Buprenorphine-Naloxone — Discount Pricing

Other medications in Pain & Inflammation

• Butorphanol
• Caffeine-Ergotamine
• Capsaicin
• Capsaicin Patch
• Carisoprodol
• Chlorzoxazone
• Codeine
• Dantrolene

About Buprenorphine-Naloxone

Buprenorphine naloxone is a vital medication used in the comprehensive treatment of opioid use disorder (OUD), helping individuals on their path to recovery. This medication plays a critical role in managing withdrawal symptoms and reducing cravings. At TheDrugClub, we understand the importance of affordable access to essential treatments, and we're dedicated to helping our members save on medications like buprenorphine naloxone.

Buprenorphine Naloxone: Supporting Recovery from Opioid Use Disorder

Opioid Use Disorder (OUD) is a chronic, relapsing brain disease that affects millions of individuals and families. For those seeking a path to recovery, medication-assisted treatment (MAT) has emerged as a highly effective, evidence-based approach. Among the cornerstone medications for MAT is buprenorphine naloxone, a prescription medication designed to help individuals manage their OUD.

What Does Buprenorphine Naloxone Treat?

Buprenorphine naloxone is specifically approved to treat opioid dependence. It's not a standalone cure but rather an integral part of a comprehensive treatment plan that typically includes counseling and behavioral therapies. The goal of using buprenorphine naloxone is to help individuals stabilize their lives, reduce illicit opioid use, minimize withdrawal symptoms and cravings, and support long-term recovery.

How Does Buprenorphine Naloxone Work?

This medication is a combination of two active ingredients: buprenorphine and naloxone.

• Buprenorphine: This component is a partial opioid agonist. This means it binds to the same opioid receptors in the brain as other opioids but produces a weaker effect. By doing so, it helps to alleviate withdrawal symptoms and reduce cravings

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Buprenorphine-Naloxone is approved for (FDA label)

Buprenorphine and naloxone sublingual film is indicated for treatment of opioid dependence. Buprenorphine and naloxone sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support. Buprenorphine and naloxone sublingual film contains buprenorphine, a partial-opioid agonist, and naloxone, an opioid antagonist, and is indicated for treatment of opioid dependence. ( 1 ) Buprenorphine and naloxone sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 12, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Buprenorphine-Naloxone (FDA label)

Buprenorphine and naloxone sublingual film is supplied as an orange rectangular sublingual film with white printing in four dosage strengths: Buprenorphine 2 mg and naloxone 0.5 mg, Buprenorphine 4 mg and naloxone 1 mg, Buprenorphine 8 mg and naloxone 2 mg and Buprenorphine 12 mg and naloxone 3 mg Sublingual film: buprenorphine 2 mg and naloxone 0.5 mg, buprenorphine 4 mg and naloxone 1 mg, buprenorphine 8 mg and naloxone 2 mg and buprenorphine 12 mg and naloxone 3 mg.

Source: FDA prescribing information (DailyMed). Set ID: 58d2c995-c0cf-a007-e063-6394a90a3f77. SPL document ID: 58d2c9a4-6660-9e99-e063-6394a90afc44. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Buprenorphine-Naloxone (FDA label)

The following serious adverse reactions are described elsewhere in the labeling: Addiction, Abuse, and Misuse [see Warnings and Precautions ( 5.1 )] Respiratory and CNS Depression [see Warnings and Precautions ( 5.2 ) , ( 5.3 )] Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions ( 5.5 )] Adrenal Insufficiency [see Warnings and Precautions ( 5.6 )] Opioid Withdrawal [see Warnings and Precautions ( 5.7 , 5.10 )] Hepatitis, Hepatic Events [see Warnings and Precautions ( 5.8 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.9 )] Orthostatic Hypotension [see Warnings and Precautions ( 5.16 )] Elevation of Cerebrospinal Fluid Pressure [see Warnings and Precautions ( 5.17 )] Elevation of Intracholedochal Pressure [see Warnings and Precautions ( 5.18 )] Adverse events commonly observed with the sublingual/buccal administration of the buprenorphine and naloxone sublingual film are oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Alvogen, Inc. at 1-866-770-3024 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 58d2c995-c0cf-a007-e063-6394a90a3f77. SPL document ID: 58d2c9a4-6660-9e99-e063-6394a90afc44. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Buprenorphine-Naloxone (FDA label)

Buprenorphine and naloxone sublingual film is contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings and Precautions ( 5.9 ) ] . Hypersensitivity to buprenorphine or naloxone. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 58d2c995-c0cf-a007-e063-6394a90a3f77. SPL document ID: 58d2c9a4-6660-9e99-e063-6394a90afc44. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Buprenorphine-Naloxone (FDA label)

Addiction, Abuse, and Misuse : Buprenorphine can be abused in a similar manner to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Multiple refills should not be prescribed early in treatment or without appropriate patient follow-up visits. ( 5.1 ) Respiratory Depression : Life-threatening respiratory depression and death have occurred in association with buprenorphine use. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with buprenorphine and naloxone sublingual film. ( 5.2 , 5.3 ) Unintentional Pediatric Exposure : Store buprenorphine and naloxone sublingual film safely out of the sight and reach of children.

Source: FDA prescribing information (DailyMed). Set ID: 58d2c995-c0cf-a007-e063-6394a90a3f77. SPL document ID: 58d2c9a4-6660-9e99-e063-6394a90afc44. Label effective date: August 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.